Neonatal Jaundice: Managing and Preventing Hyperbilirubinemia

In neonates, the immature liver is unable to efficiently conjugate bilirubin, leading to its accumulation in the blood.

Prematurity, low birth weight, and cephalohematoma are all risk factors for developing severe neonatal jaundice.

Physiologic jaundice is the most common type of neonatal jaundice, affecting up to 80% of newborns.

Physiologic jaundice typically appears within 24 hours of birth, peaks at 3-5 days of life, and resolves by 2 weeks of life.

Physiologic jaundice is a benign condition that typically resolves on its own without treatment.

Phototherapy is indicated for the treatment of neonatal jaundice when the total serum bilirubin level exceeds 15 mg/dL.

Phototherapy converts bilirubin to a water-soluble form, allowing it to be excreted in the urine and feces.

The most common adverse effect of phototherapy is a skin rash, which typically resolves after discontinuation of treatment.

Phototherapy is typically continued until the total serum bilirubin level is <10 mg/dL.

Breastfeeding should be encouraged as it helps to prevent jaundice by promoting the passage of bilirubin from the infant's gut.

Breast milk jaundice is a benign condition that typically resolves on its own. Breastfeeding should be continued and the infant's bilirubin levels should be monitored closely.

The management of pathologic jaundice depends on the underlying cause and may include phototherapy, intravenous immunoglobulin, and exchange transfusion.

The goal of exchange transfusion in the treatment of neonatal jaundice is to remove bilirubin from the infant's blood.

The most common complications of exchange transfusion include infection, thrombosis, and hypocalcemia.

The long-term outcomes of neonatal jaundice can include kernicterus, hearing loss, and intellectual disability.